© 1983 Oxford University Press
research-article |
Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin
Department of Surgery, Akita University School of Medicine Akita 010, Japan
The non-steroid anti-inflammatory drug indomethacin, a prostaglandin synthesis inhibitor, may play a role to prevent the chemically induced colon cancer development in rats. CD-Fischer rats were given 3 intrarectal doses of 4 mg N-methyl-N-nitrosourea in week 1 as an initiation procedure to induce colon cancer. The experimental groups received a 0.001% water solution of indomethacin freely as drinking water at various times either during the initiation stage or the subsequent promotion stage. At autopsy in week 31, the treatment reduced the colon cancer development in the group of rats treated for week 1 (initiation stage), and for week 2–30 (early and late promotion stages) and for week 11–30 (late promotion stage), compared with untreated controls. However, removal of the treatment after effective treatment in promotion stage permitted the cancer development, and it suggests that the initiated cells are surviving during the treatment in promotion stage. It is concluded that indomethacin may inhibit methylnitrosourea-induced initiation and regulate promotion in colon carcinogenesis, presumably correlated with an inhibition of prostaglandin synthesis in the colon by indomethacin.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vogiagis, W. Brown, E. M. Glare, and P. E. O'Brien Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels Carcinogenesis, June 1, 2001; 22(6): 869 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Wilson and C. S. Potten The Effect of Exogenous Prostaglandin Administration on Tumor Size and Yield in Min/+ Mice Cancer Res., August 1, 2000; 60(16): 4645 - 4653. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process Cancer Res., July 1, 1999; 59(14): 3387 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ding, Z. Dong, F. Chen, D. Pack, W.-Y. Ma, J. Ye, X. Shi, V. Castranova, and V. Vallyathan Asbestos Induces Activator Protein-1 Transactivation in Transgenic Mice Cancer Res., April 1, 1999; 59(8): 1884 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dong, C. Huang, R. E. Brown, and W.-Y. Ma Inhibition of Activator Protein 1Activity and Neoplastic Transformation by Aspirin J. Biol. Chem., April 11, 1997; 272(15): 9962 - 9970. [Abstract] [Full Text] [PDF]
|
|